The new plant, which has been inspected by the Medicines and Healthcare products Regulatory Agency (MHRA), is intended to provide access to clinical manufacturing capabilities for all the drug development companies worldwide.
Built with an investment of £9m, the new 30,000ft2 plant is designed to handle a series of non-sterile dosage forms, including solids, liquids, semi-solids and inhaled products.
The facility will feature up to six GMP suites, new laboratories and a dedicated clinical packing area to support clients’ Phase I and II clinical trial projects.
Molecular Profiles CEO Nikin Patel said, "From a commercial perspective, we are very much open for business and have already received significant interest from companies looking to use our manufacturing capabilities to assist with their clinical trial requirements."